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Abstract Article Info 
Introduction: Measurement of the mean platelet volume (MPV) is a simple, inexpensive, useful, easy to apply 
test without additional costs. A high MPV value indicates the presence of large and active platelets in the 
peripheral blood vessels. Increased MPV value can be a biomarker of nasopharyngeal carcinoma (NPC) 
malignancies as well as a warning of the risk of thrombosis in malignancy. 
Objective: To investigate the differences of mean platelet volume (MPV) value among clinical stage of 
undifferentiated type nasopharyngeal carcinoma (NPC) patient at ORL-HNS outpatient, Sanglah General 
Hospital Denpasar. 
Methods: A cross-sectional study with 30 undifferentiated types of NPC patient in ORL-HNS outpatient at 
Sanglah Hospital Denpasar from January 2017 to December 2019. The sample was selected by systematic 
random sampling. The analysis used the ANOVA difference test to determine the difference in MPV values 
among the clinical stage of the undifferentiated type of NPC patient. 
Results: In this study, the mean age of NPC patients was 50.70 with a standard deviation of 12.55 with the most 
NPC patients were found to be at the age of more than 50 years. The proportion of NPC patients based on sex 
was found more in men with 19 patients (63.3%). The mean of MPV value was 12.40 with a standard deviation 
of 1.27. The highest distribution of undifferentiated types NPC patients among the clinical stage, at stage III and 
IVA, with 12 patients (40%). The MPV values among clinical stage in patients with undifferentiated type of 
NPC is significantly different with P= 0.012. 
Conclusion: In this study there was a significant difference between the MPV value among the clinical stage of 
the undifferentiated type of NPC in ORL-HNS Outpatient, Sanglah General Hospital with P= 0.012. 
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NPC is endemic in southern China and Southeast Asia including 
Indonesia with a low survival rate for sufferers [1, 2]. Although it is the most 
common malignancy found in the head and neck, biomarkers that are 
clinically proven in the prognosis of NPC therapy are still less effective [3].  
Measurement of the mean platelet volume (MPV) is a simple, useful, 
easy to apply test without additional costs. In addition, MPV describe the 
diameter of platelet, which can be indicator of platelet activation. Thus, if 
there are large and active platelets in the peripheral blood vessels, the MPV 
value will increase. These platelets express platelet-derived growth factor 
(PDGF), thromboxane A2, glycoprotein Ib and IIb/IIIa receptors in excess. 
The production of these substances, especially PDGF, can increase 
thrombosis in patients with malignancy and is associated with the growth 
rate and invasion of malignant tumours. MPV is reported as a prognostic 
factor and therapeutic evaluation for several types of cancer [4]. 
Increased MPV value can be a significant biomarker of head and neck 
malignancies as well as a warning of the risk of thrombosis in malignancy. 
Increased thrombosis in head and neck malignancies has been reported in 
several studies [5]. Zhang et al. use MPV as a platelet activation scoring 
system to evaluate the relationship between several clinical variables and 
overall survival and disease-free survival where it was found that MPV had 
the best discriminatory ability as lymph node metastasis status. This study 
proved that MPV biomarkers had prognostic value in 468 nasopharygeal 
carcinoma patients with histopathological squamous cell type compared to 
undifferentiated type [6]. 
 
2. MATERIALS AND METHODS 
The research design used in this study was a cross-sectional design 
by taking retrospective data from the medical records of patients with 
undifferentiated types of NPC in ORL-HNS outpatient at Sanglah 
Hospital Denpasar from January 2017 to December 2019. The sample 
was selected by systematic random sampling with 30 samples . The 
selected sample met the inclusion criteria, namely NPC patients with 
undifferentiated types and had performed laboratory supporting 
examinations, CT-scans and chest radiographs for clinical stage 
enforcement, with exclusion criteria, namely NPC patients with a 
history of cardiovascular disease, hematology disease, history of 
consumption of antiplatelet drugs in the last 3 months, and incomplete 
medical records. 
Data recording includes clinical information in the form of name, 
sex, age, registration number, telephone number, medical history and 
drug consumption history, clinical stage and MPV value. Data from the 
results of the examination were recorded in a data collection sheet then 
tabulated and analyzed. 
The data analysis conducted in this study was univariate and bivariate 
analysis. Univariate analysis aims to describe the characteristics of 
research subjects and research variables. Variables that are scaled to 
numeric data are shown as means and standard deviation. Variables that 
were of a categorical scale were displayed using numbers and percentages 
(relative frequency). The results of the univariate analysis will be 
displayed in the form of a single distribution table. The bivariate analysis 
used the ANOVA difference test to determine the difference in MPV 















Table 1. The characteristics of research subjects 
Characteristics n = 30 
Age (year) 
   Mean ± SD 
   Min – Max  
Age category 
<20 year old 
21 – 30 year old 
31 – 40 year old 
41 – 50 year old 
>50 year old 
 
50.70 ± 12.55 








   Male 
   Female 
Mean Platelet Volume (MPV) 
   Mean ± SD 





12.40 ± 1.27 
10.51 – 15.40 
 
The mean age of NPC patients in this study was 50.70-year-old with 
a standard deviation of 12.55, the youngest was 20-year-old and the 
oldest was 73-year-old. In the age category, the most NPC patients were 
found to be at the age of more than 50 years, as many as 15 patients or 
50%. The proportion of NPC patients based on sex was found more in 
men, 19 patients (63.3%) and 11 women (36.7%). The mean of MPV 
value was 12.40 with a standard deviation of 1.27. 
In this study, the highest distribution of undifferentiated types NPC 
patients among the clinical stage based on AJCC 2018, at stage III and 
IVA, with 12 patients or 40%, followed by stage II with 4 patients 
(13.3%) and stage IVB as many as 2 patients (6.7%). The distribution 
of undifferentiated types of NPC patients on its clinical stage is shown 
in Table 2. 
Table 2. The distribution of undifferentiated type of NPC patients based on 
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Table 3 shows the difference in MPV values among clinical stage in 
patients with undifferentiated type of NPC. It can be seen that the mean 
MPV value among clinical stage is significantly different with P= 0.012. 
Table 3. Differences in MPV values among clinical stage in patients with 
undifferentiated type of NPC 









7.14 – 15.27 
11.47 – 12.52 
11.74 – 13.56 
10.93 – 15.96 
0.012 
4. DISCUSSION 
In this study, it was found that the sex of NPC patients with the highest 
frequency was male as many as 19 people (63.3%). This result is in 
accordance with previous research conducted at Sanglah General Hospital 
[7]. Several studies in various countries also show that there are more male 
NPC patients than women with an average ratio of 2-3:1 [8]. NPC patients 
were more often found in men than women reported in almost all studies, 
this is thought to be related to life and work habits that cause men to be 
frequently exposed to carcinogens that cause NPC. Exposure to carcinogens 
agent in the workplace, such as chemical gases, dust fumes and smoke 
increases the NPC risk 2 -6 times, while formaldehyde increases the risk of 
NPC 2-4 times [7]. 
In this study it was also seen that the age distribution of NPC patients 
with the highest frequency was >50 years as many as 15 people (50.0%), 
while the lowest frequency was found to be the same in the 21-30 year age 
group, where there were no patients at that age (0.0%). This finding is in 
accordance with Earnesty's research in 2018. Although not exactly the same, 
it is in line with other researchers who get the most NPC patients in the 36-
60 year age group [7, 9]. The 41-60 year age group is the highest proportion 
of the population according to the research Puspitasari (2011) at RSUP H. 
Adam Malik Medan and Pua (2008) in Malaysia. Hasibuan, et al., (2014) 
also found that the most age group of NPC sufferers was the 41-60 year 
group. This is because the DNA repair mechanism system that has mutated 
is not functioning properly and the body's immune system decreases at the 
age of more than 40 years so that patients with malignancy are more likely 
to occur in old age [9]. 
In this study, it was found that the distribution of clinical stage of NPC 
patients with the highest frequency was at stage III and IV A as many as 12 
patients (40.0%), while the lowest frequency was found in the stage I group 
of 0 patients (0%). This is in accordance with previous research conducted 
by Danastri (2019) at Sanglah Denpasar Hospital. Research conducted by 
Earnesty (2018) and Hasibuan, et al. (2014) at RSUP H. Adam Malik Medan 
also got a similar result. Early symptoms of NPC are not typical, similar to 
an upper respiratory tract infection so that they don't get enough attention 
from the patient or the examining doctor. In addition, the location of the 
tumor hidden in the nasopharynx, inadequate equipment, inadequate 
knowledge, trust in non-medical treatment, fear of seeing a doctor and the 
patient's weak socio-economic condition often become obstacles in making 
a diagnosis of this disease. Therefore, early symptoms of NPC are often 
overlooked and patients are diagnosed after the size of the tumor and 
enlarged large lymph nodes at an advanced stage so that patients often come 
for treatment when they are at an advanced stage [9]. 
In this study, it was found that the mean MPV value of NPC patients 
before undergoing chemotherapy was 12.40 ± 1.27 fl with the lowest value 
of 10.51 fl and the highest was 15.40 fl. This is similar to the study by 
Earnesty (2018) which found that the mean MPV value of NPC patients 
before undergoing therapy was 10.28 ± 1.24 fl. The results of this study 
indicate that in NPC patients there was an increase in the MPV value above 
normal (6.8 - 10.0 fl) [9]. 
The increase in MPV value in NPC patients reflects an increase in the 
diameter of the platelets. A large platelet size is a marker of high platelet 
activity, where platelets facilitate the formation of circulating tumor cells, 
protecting tumor cells from attacks originating from the host such as 
immune attack and apoptosis and regulating intravasation/extravasation of 
circulating tumor cells. Cytokines and receptors derived from platelets are 
involved in this cascade [10]. 
In this study it was proven that the mean MPV value higher in patient 
with higher stage of NPC patients than patient with lower stage  (P= 0.012). 
It appears that patients with stage IV B have the highest mean MPV value, 
with 13.45 fl. This finding is in accordance with the research of Earnesty 
(2018) which found that there were significant differences in mean MPV 
values between clinical stages of undifferentiated type of NPC. This study 
obtained the highest mean MPV value in patients with NPC stage IV, namely 
10.49 with P<0.01 [9]. 
This study found that the mean MPV value in NPC patient with 
metastasis stage (IV B) was higher than other stages. Metastasis is the 
leading cause of death from malignancy. In metastasis process, some cancer 
cells (circulating tumor cells), regardless of the primary location, enter the 
circulating bloodstream, extravasate and proliferate at the site of metastasis. 
The presence of circulating tumor cells in malignant patients is associated 
with a poor prognosis because these cells are able to reach secondary organs 
before the onset of clinical symptoms. Thrombocytosis in patients with 
metastatic malignancy, indicating the important role of platelets in this 
process . So that in patients with metastatic NPC, there will be an increase 
in platelet activity, which is further illustrated by an increase in the MPV 
value [10]. 
Sehitoglu et al. (2016) reported that increasing the MPV value is not 
only important in the process of invasion and recurrence of Kaposi's 
sarcoma, but also important for therapeutic response. They reported an 
increase in the MPV value in Kaposi sarcoma patients and the MPV value 
increased according to the stage, as well as a higher MPV value in Kaposi 
sarcoma patients who had relapsed. Keles, et al. (2014) in their research of 
104 patients with renal cell carcinoma found the lowest MPV mean value 
was found at stage I and increases with increasing clinical stage [4]. 
Evidence for an association between MPV values and cancer stage was 
also reported in other cancers, such as colon, blood, kidney, liver and 
endometrial. The mechanism is very clear, where IL-6 will produce massive 
and giant active platelets. Therefore, the number and volume of platelets in 
higher stage of malignancy will increase than the benign disease  [6]. 
Epithelial-mesenchymal transitions, or mesenchymal-epithelial 
transitions, play an important role in increasing migration and invasion 
capacity, resistance to apoptosis, and increasing extracellular matrix 
components. Lou et al. (2015) showed the expression of proteins related to 







epithelial-mesenchymal transitions, such as cytokeratin (CK), E-cadherin, 
vimentin and N-cadherin. Platelet aggregation induce platelets to release 
alpha granules, which contain TGF-β and high platelet-derived growth 
factor (PDGF). Platelet-derived TGF-β activates the SMADs signaling 
pathway and the trans-differentiation of circulating tumor cells into 
mesenchyme-like phenotypes. Platelet-derived growth factor provide 
epithelial-mesenchymal transition that contributes to cancer angiogenesis. 
In addition, TGF-β was shown to increase the expression of PDGF and 
PDGF receptors through β-catenin activation and signal transducer and 
activator of transcription 3 (STAT3) [10]. 
This research is important because most people with NPC often 
experience an increase in MPV levels, which indicates the large and reactive 
platelets, which causes an increase the accumulation of prothrombic factors, 
which are known to cause microvascular and macrovascular pathologies in 
malignancies [3]. MPV value correlates with the characteristics of 
malignant patients where high MPV values express PDGF, thromboxane 
A2, excessive glycoprotein Ib and IIb / IIIa receptors which can increase the 
occurrence of thrombosis and growth rate and invasion of malignant tumors, 
markers of angiogenesis, metastasis and proteolysis in the process of 
malignant inflammation and be a prognostic factor [4, 11]. Measurement of 
the MPV value is a simple, inexpensive, useful, easy to apply test, without 
additional costs [4], so it is hoped that the MPV value is also used as a 
predictor of prognosis and therapeutic success biomarkers in patients with 
undifferentiated types of NPC. 
Earnesty (2018) found that the MPV value in NPC patients was found 
to be more increased in the male sex group, amounting to 137 patients 
compared to the female sex group [9]. The prevalence of NPC tends to be 
more prevalent in males than females due to the pattern and lifestyle as well 
as environmental factors towards carcinogenic exposure which is more 
dominant in males. In many studies it has been proven that the MPV value 
in NPC patients is found to be the most increased in the age group> 50 years. 
Verdoia et al. (2015) found that advancing age was directly related to greater 
mean platelet volume, but did not contribute to explaining the higher 
prevalence and rates of coronary artery disease in elderly patients [9]. 
Meikle et al. (2016) suggested that the role of platelets in cancer 
development and metastasis is: (1) aggregates with tumor cells; (2) induces 
tumor growth, epithelial-mesenchymal transition and invasion; (3) protects 
circulating tumor cells from the immune system; (4) facilitates the 
withdrawal and capture of circulating tumor cells; and (5) inducing 
angiogenesis and distant tumor cell formation. Platelets activated by tumor 
cells also predispose cancer patients to thrombotic events. [12]. 
Platelets contain both angiostatic and angiogenic factors, where the 
transition to the angiogenesis phenotype can be triggered by metastasis. Tumor 
cells initiate platelet aggregation by binding von Willebrand factor, then 
releasing VEGF. Protease-activated receptor-1 (PAR-1) ligation trigger the 
release of VEGF alpha granules. Activation of PAR-4 upregulates the secretion 
of endostatin, an angiogenesis inhibitor derived from platelets [10]. 
MPV indicate the angiogenesis in malignancy patient because of its role 
as angiogenic, metastatic and proteolytic in the inflammatory process of 
malignancy. Tumor cells have a direct effect on platelet production and 
activation by release mediators, procoagulants, fibrinolytic factors, 
proteases and cytokines, and through adhesion molecules can interact 
directly with thrombosis [13,14]. 
It is well known that the term Trousseau syndrome is used to describe 
the thromboembolic manifestations that occur in cancer patients. These 
include thrombosis (venous and arterial), nonbacterial thrombotic 
endocarditis, microangiopathic thrombosis and veno-occlusive disease. 
Deep vein thrombosis of the lower extremities is the most frequent clinical 
manifestation followed of the upper limb, pulmonary embolism, cerebral 
sinus thrombosis and displaced superficial thrombophlebitis. Large 
prospective and retrospective population studies show the incidence of 
venous thromboembolism varies from 0.6%-7.8% [15]. 
Another clinical manifestation is microangiopathic thrombosis which is 
a heterogeneous group of diseases characterized by microangiopathic 
hemolytic anemia, peripheral blood thrombocytopenia and various degrees 
of organ failure. This group of diseases has been reported in cancers that 
received certain chemotherapy such as mitomicin, gemsitabin and recently 
reported on targeted therapies such as monoclonal antibodies and tyrosine 
kinase inhibitors [16, 17]. 
Veno-occlusive disease is found in severe liver disease characterized by 
intrahepatic small central venule obstruction by microthrombi and fibrin 
buildup and is reported in about 50% - 60% of bone marrow transplant 
patients. Risk factors for this are liver damage, high doses of chemotherapy 
drugs, abdominal radiation, female sex and differences in human leukocyte 
antigens. In addition, thrombosis can be an early clinical sign of an 
undiagnosed cancer. Patients with idiopathic venous thromboembolism 
have 4-7 times the risk of being diagnosed with cancer within 1 year of 
known thrombosis. The risk of being diagnosed with cancer in this group is 
greater if there is recurrent and bilateral venous thromboembolism [17]. 
The imbalance of the coagulation system in very complex involving 
various factors, both clinical and biological factors. Clinical risk factors for 
venous thromboembolism can be grouped into patient-related factors, 
cancer-related factors and therapy-related risk factors. Old age, African-
American race, presence of comorbids (infection, kidney disease, lung 
disease, obesity, according to the Charlson comorbidity index) have a higher 
risk. Primary sites for tumors of the brain, pancreas, stomach, kidney, 
ovaries and lungs are at high risk. Patients with hematological malignancies 
such as lymphoma and myeloma have a high risk as well. The risk of venous 
thromboembolism is high in the first 3 months after diagnosis. From the 
aspect of cancer therapy will increase the risk of venous thromboembolism. 
Cancer patients who underwent surgery had a two times higher risk of 
developing postoperative venous thromboembolism than non-cancer 
patients. This risk persists for more than 7 weeks postoperatively. Use of 
systemic chemotherapy is associated with a 2-6 times increased risk 
compared to the general population. Antiangiogenesis group chemotherapy 
therapy, especially thalidomide and lenalidomide, has a higher risk when 
combined with dexamethasone or other chemotherapy. The chemotherapy 
regimen containing bevacizumab increases the risk of arterial 
thromboembolism. This also applies to sunitinib and sorafenib [15]. 
Increased MPV value can be a significant biomarker of head and neck 
malignancies as well as a warning of the risk of thrombosis in malignancy. 
The incidence of thrombosis in head and neck malignancies has been 
reported in several studies [5, 18]. 
Eryilmaz, Basal and Omurlu (2015) suggested that MPV values in head 
and neck malignancies is highest than the control group [19]. An increase in 
MPV values in patients with papillary carcinoma of the thyroid compared 
to patients with benign goiter was reported by Baldane (2015) and in this 
study they also had a decrease in MPV values after surgery [20]. 
Cihan and Baykan (2015) found a statistically significant difference in 
mean MPV. An increase in MPV values was found in patients with skin 
cancer types of basal cell carcinoma and squamous cell carcinoma compared 
to healthy controls and statistically significant. Osada et al. reported that 
MPV is an accurate diagnostic parameter in patients with gastric cancer. [3]. 
Ulutas and Sarici (2016) suggest that an increase in the MPV value in a 
group of patients newly diagnosed with pancreatic cancer is a reflection of 
an ongoing inflammatory process and can be associated with increased 
levels of cytokines, especially IL-6, so that the MPV value can be used to 
detect pancreatic cancer [21].  
5. CONCLUSION 
Conclusion conducted clear and concise and able to give a brief 
summary of the study. In this study there was a significant difference 
between the MPV value among the clinical stage of the undifferentiated type 
of NPC in ORL-HNS Outpatient, Sanglah General Hospital with P=0.012.  
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